

Published in final edited form as:

*Chem Asian J.* 2008 March 7; 3(3): 548–552. doi:10.1002/asia.200700301.

## Monodisperse Magnetite Nanoparticles Coupled with Nuclear Localization Signal Peptide for Cell-Nucleus Targeting

Chenjie Xu<sup>[a]</sup>, Jin Xie<sup>[a]</sup>, Nathan Kohler<sup>[b]</sup>, Edward G. Walsh<sup>[c]</sup>, Y. Eugene Chin<sup>[d]</sup>, and Shouheng Sun<sup>\*,[a]</sup>

[a]Department of Chemistry, Brown University, Providence, Rhode Island 02912 (USA)

[b]Brown Medical School, Brown University, Providence, Rhode Island 02906 (USA)

[c]Department of Neuroscience, Brown University, Providence, Rhode Island 02912 (USA)

[d]Department of Surgery, School of Medicine, Brown University, Providence, Rhode Island 02903 (USA)

### Abstract

Functionalization of monodisperse superparamagnetic magnetite (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles for cell specific targeting is crucial for cancer diagnostics and therapeutics. Targeted magnetic nanoparticles can be used to enhance the tissue contrast in magnetic resonance imaging (MRI), to improve the efficiency in anticancer drug delivery, and to eliminate tumor cells by magnetic fluid hyperthermia. Herein we report the nucleus-targeting Fe<sub>3</sub>O<sub>4</sub> nanoparticles functionalized with protein and nuclear localization signal (NLS) peptide. These NLS-coated nanoparticles were introduced into the HeLa cell cytoplasm and nucleus, where the particles were monodispersed and non-aggregated. The success of labeling was examined and identified by fluorescence microscopy and MRI. The work demonstrates that monodisperse magnetic nanoparticles can be readily functionalized and stabilized for potential diagnostic and therapeutic applications.

### Keywords

cell imaging; magnetic resonance imaging; magnetite; nanoparticles

### Introduction

Functionalization of monodisperse superparamagnetic magnetite (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles for cell-specific targeting is crucial for cancer diagnostics and therapeutics.[1-4] Targeted magnetic nanoparticles can be used to enhance the tissue contrast in magnetic resonance imaging (MRI),[5,6] to improve the efficiency in anticancer drug delivery,[7,8] and to eliminate tumor cells by magnetic fluid hyperthermia.[9-11] Recent synthetic progress makes it possible to produce mono disperse iron oxide nanoparticles with controlled sizes and magnetic properties,[12-15] but interactions between these nanoparticles and biomolecular entities, especially various tumor cells, are rarely studied owing to the challenge in nanoparticle functionalization and stabilization.[6,16] Herein we report a robust surface-functionalization approach to link monodisperse Fe<sub>3</sub>O<sub>4</sub> nanoparticles with nuclear localization signal (NLS) peptide and test their capability in targeting tumor-cell nuclei. In vitro experiments showed that the uptake of the NLS-labeled nanoparticles by HeLa cells is increased by up to 233%

over the non-NLS-labeled nanoparticles. More importantly, the morphology of the nanoparticles during the uptake process was unchanged. These nanoparticles and their presence in nuclei were characterized by fluorescent microscopy, magnetic resonance imaging (MRI), and transmission electron microscopy (TEM). The work demonstrates that, through proper surface functionalization, it is possible to stabilize and deliver monodisperse Fe<sub>3</sub>O<sub>4</sub> nanoparticles into tumor-cell nuclei for sensitive diagnostic and efficient therapeutic applications.

NLS represents a group of oligopeptides that contain a short amino acid sequence. It is known to act as a 'vector' to direct the protein into the cell nucleus through the nuclear pore complex, [17,18] and was recently applied to Au- and dextran-coated iron oxide nanoparticles for their targeting to cell nuclei.[19-22] Different from these previous functionalization steps, our approach is to conjugate biotinylated NLS to monodisperse Fe<sub>3</sub>O<sub>4</sub> nanoparticles through NeutrAvidin (NAv) and a surfactant combination of polyethylene glycol (PEG) and dopamine (DPA), or 4-(2-aminoethyl)benzene-1,2-diol. DPA can form a strong chelate chemical bond with the iron oxide surface,[23,24] and PEG has been used widely to protect nanoparticles for their stabilization under physiological conditions.[25,26]

## Results and Discussion

The monodisperse 9-nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles were prepared with a hydrophobic coating of oleate and oleylamine according to a previous publication.[7] To render these nanoparticles hydrophilic, we first linked DPA with one COOH group in bis{2-[(3-carboxy-1-oxopropyl)amino]ethyl}polyethylene glycol ( $M_n=3000$ ) by using conventional *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide/*N*-hydroxysuccinimide ester (EDC/NHS) chemistry to synthesize NaOOC-PEG-CONH-DPA. This NaOOC-PEG-CONH-DPA was then used to replace oleate/oleylamine around the synthesized nanoparticles in CHCl<sub>3</sub>/DMF solution by the formation of a chelate bond between Fe<sub>3</sub>O and DPA.[8] Thermogravimetric analysis revealed that each Fe<sub>3</sub>O<sub>4</sub> nanoparticle contained about 32 PEG units. NeutrAvidin (NAv) was then conjugated to the -COONa group in NaOOC-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> by means of EDC/NHS chemistry to give NAv-NHOC-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> (Figure 1 a). The NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles were further functionalized with a biotinylated NLS peptide (KKKRKV) by conjugating the peptide to NAv through biotin-avidin interaction. HeLa cells were chosen for the functionalized nanoparticle penetration and targeting.

Figure 1 b and c show the TEM images of the monodisperse 9-nm Fe<sub>3</sub>O<sub>4</sub> nanoparticles prior and subsequent to surface modification with DPA-PEG-NAv. One can see that the nanoparticles are well dispersed under both conditions. The hydrodynamic sizes of the nanoparticles in the dispersions measured by dynamic light scattering (DLS) (Figure 2) revealed that the overall diameter of the nanoparticles was increased from ~13 nm in the synthesized Fe<sub>3</sub>O<sub>4</sub> to ~50 nm in the functionalized NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles after ligand exchange. Gel electrophoresis analysis of the NaOOC-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> and NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticle dispersions showed that NAv was closely associated with the nanoparticles (Figure 3).

The dispersion stability of the NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> and NLS-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles was further tested by measuring their hydrodynamic size change during the incubation in buffer solution. The nanoparticles were dispersed in phosphate-buffered saline (PBS), or PBS plus 10% fetal bovine serum (FBS) and were incubated under ambient conditions at 37 °C. The incubated dispersion was sampled at different time periods and the average hydrodynamic size of the nanoparticles in each sample was measured by DLS. Figure 4 gives the measurement results from NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> and NLS-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticle dispersions. After incubation for 72 h, the average size of these NAv-

and NLS-modified nanoparticles maintains a hydrodynamic diameter of ~50 nm and ~60 nm for the dispersion in PBS and ~60 nm and ~80 nm for the dispersion in PBS+10% FBS, respectively (Figure 4). The size increase of the functionalized nanoparticles in PBS+10% FBS is presumably due to the interaction between the negatively charged FBS and the functionalized nanoparticle surface that bears the positively charged NLS peptide.

To examine the dispersity of NLS peptide-nanoparticles in cells, we introduced the particles into the HeLa cells. By labeling NeutrAvidin with a fluorescent dye, rhodamine (RA), prior to PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticle conjugation, the location of the particles can be monitored through fluorescence microscope. RA-labeled VKRKKK-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> or RA-labeled NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> were incubated with HeLa cells under the same conditions—120 min in Dulbecco's Modification of Eagle's Medium (DMEM) buffer containing 3.7 mM NaHCO<sub>3</sub> and 0.1% bovine serum albumin plus 10% FBS. The cells were washed with PBS to remove extra nanoparticles. HeLa cells incubated with RA-labeled VKRKKK-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles had more fluorescent signal in the nucleus (Figure 5) than those incubated with RA-labeled NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub>. To characterize the detailed location of the nanoparticles within the cells, we incubated the HeLa cells with DAPI (4',6-diamidino-2-phenylindole)[9]—a blue-fluorescent molecule that can bind preferentially to double-stranded DNA in the nucleus to produce a fluorescent enhancement for nucleus image (Figure 5 b). The pink image yielded from overlaying of DAPI staining and the RA staining is shown in Figure 5 c, indicating that the NLS peptide delivers the nanoparticles into the nuclei in HeLa cells. However, the particles without NLS peptide could not enter the nucleus (Figure 5 d-f). The average iron concentration in each cell that was incubated with NLS or non-NLS-functionalized nanoparticles was measured by inductively coupled plasma atomic emission spectrometry (ICP-AES) (Figure 5 g). The NLS-nanoparticle sample (0.01 mg Fe mL<sup>-1</sup>) exhibited an increase in uptake of 233±20%.

The effect of these nanoparticles on the  $T_2$  relaxation of the free water within the HeLa cells was further tested with MRI. Figure 5 h shows the MRI image obtained from the HeLa cells treated with the NLS-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticle sample (the first row) or the NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticle sample (the second row) at different concentrations as indicated. The relaxivity  $r_2$  of the particles in cells is 68.6 s<sup>-1</sup> mM<sup>-1</sup>. There is no apparent difference in terms of the signal intensity between the cells containing NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles and the cells containing no particles (control). In contrast, images from the cells containing NLS-biotin-NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles are darker, indicating that the nanoparticles within the cells do offer a contrast enhancement in MRI.

The stability of fluorescent magnetic nanoparticles in the cell and the nucleus was examined by TEM. Figure 6 a-c shows the uptake of the NLS-peptide nanoparticles by a single HeLa cell after incubation of the cells with the NLS peptide-nanoparticles for a period of 2 h. In contrast to the aggregation of other particles inside the cells, DPA-PEG-modified Fe<sub>3</sub>O<sub>4</sub> showed great monodispersity in the cell cytoplasm and nucleus. It can be seen that the nanoparticles are extensively dispersed in the cytoplasm without apparent aggregation, except for a small portion of those in the endosomes (Figure 6 a). Figure 6 b demonstrates that the NLS nanoparticles entered the cell nucleus and Figure 6 c is a close-up view of a small area around the nuclear membrane. It can be seen that the well-dispersed nanoparticles are spread in the nucleus. In contrast, most of the NAv nanoparticles are seen in cytoplasm area (Figure 6 d), indicating that the non-NLS nanoparticles do not translocate into the nucleus. The mechanism of the nanoparticle uptake is believed to be through endocytosis,[10] but how these particles escape from endosome and are still monodispersed is under investigation.

## Conclusions

We have shown that monodisperse Fe<sub>3</sub>O<sub>4</sub> nanoparticles prepared by an organic-phase synthesis are readily functionalized with hydrophilic DPA-PEG-based surfactant and stabilized under physiological conditions. The NLS-peptide-coated nanoparticles show preferred uptake by HeLa cell nuclei over the non-NLS-labeled nanoparticles. A similar synthetic strategy can be used to coat monodispersed iron oxide based nanoparticles with various signal peptides, genes, or drugs and to deliver them to specific organelles. These will allow detailed studies of uptake mechanisms of the particles by cells, especially tumor cells. A deeper understanding will help to create novel functional magnetic nanoprobe that are suitable for highly sensitive medical diagnostics and highly efficient drug/gene delivery.

## Experimental Section

### Chemicals and Materials

$\alpha,\omega$ -Bis(2-carboxyethyl)polyethylene glycol (MW=3,000), dopamine hydrochloride, and sodium carbonate were purchased from Sigma-Aldrich. NeutrAvidin, *N*-hydroxysuccinimide (NHS), and *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (EDC) hydrochloride and 4',6-diamidino-2-phenylindole (DAPI) were obtained from Pierce Biotechnology. All organic solvents were purchased from Sigma-Aldrich Corp. All the buffers and media used were acquired from Invitrogen Corp. The water was purified by a Millipore Milli-DI Water Purification System. Nano-sep 100k OMEGA was purchased from Fisher. All the dialysis bags were purchased from Spectrum Laboratories, Inc.

### Nanoparticles Synthesis

Fe(acac)<sub>3</sub> (2 mmol) was dissolved in a mixture of benzyl ether (10 mL) and oleylamine (10 mL). The solution was dehydrated at 110 °C for 1 h. Then it was quickly heated to 300 °C and kept at this temperature for 2 h. Ethanol (50 mL) was added to the solution after it cooled down to room temperature. The precipitate was collected by centrifugation at 8000 rpm and was washed with ethanol (3×40 mL). Finally, it was redispersed in hexane (10 mL).

### Modification

$\alpha,\omega$ -Bis{2-[(3-carboxy-1-oxopropyl)amino]ethyl}polyethylene glycol (20 mg), NHS (2 mg), EDC (3 mg), and dopamine hydrochloride (1.27 mg) were dissolved in a mixture of CHCl<sub>3</sub> (2 mL), DMF (1 mL), and anhydrous Na<sub>2</sub>CO<sub>3</sub> (10 mg). The solution was stirred at room temperature for 2 h, and then Fe<sub>3</sub>O<sub>4</sub> nanoparticles (5 mg) were added. The resulting solution was stirred overnight at room temperature under N<sub>2</sub>. The modified Fe<sub>3</sub>O<sub>4</sub> nanoparticles were precipitated by adding hexane, collected by using a permanent magnet, and dried under N<sub>2</sub>. The particles were then dispersed in water or PBS. The extra surfactants and other salts were removed by dialysis (dialysis bag; MWCO=10 000) for 24 h in PBS or water. Any precipitation (almost none in the synthesis) was removed by using a 200-nm syringe filter (Millipore Corp.). The final concentration of the particles was determined by ICP-AES analysis.

### Labeling NeutrAvidin with Rhodamine

NAv was incubated with RA in Na<sub>2</sub>CO<sub>3</sub>/NaHCO<sub>3</sub> (pH 9) buffer at room temperature for 1 h (RA/NAv 10:1). The final conjugate was purified by removing the extra free RA through the PD-10 column (GE Healthcare Corp.).

## HeLa Cell Labeling with RA-Labeled NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> or NLS-Biotin-NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> Nanoparticles

HeLa cells were cultured in a glass-bottomed Petri dish (MatTek Corp.) with DMEM plus FBS (10%) and antibiotics (1%). Before incubation with the particles, the cells were washed three times with PBS. The particle solution in DMEM media was then incubated with the cells for 2 h. The cells were washed three times with PBS and fixed in paraformaldehyde (4%). After fixation for 30 min, the cells were washed three times with PBS before being analyzed by fluorescence microscopy (Nikon Eclipse TE2000-U) or MRI. To counterstain HeLa cells, DAPI was dissolved (30 nM) in PBS and mixed with the cells for 5 min after paraformaldehyde fixation followed by PBS washes.

### Preparation of HeLa Cell Samples for TEM

The NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> and NLS-biotin-NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles were dispersed in the cell culture medium (DMEM with 10% FBS, 1% antibiotic) at a concentration of 0.01 mg Fe mL<sup>-1</sup>. The mixture was incubated for 2 h and washed twice with PBS to remove the excess particles. The cells were detached with trypsin EDTA (0.05%) and fixed with modified Karnovsky's Fixative (2% paraformaldehyde and 2% glutaraldehyde in PBS) before they were post-fixed in OsO<sub>4</sub> (1%) for 1.5 h, stained with uranyl acetate (2%) for 2 h, and dehydrated in alcohol and propylene oxide. The treated cells were then embedded in eponate resin, sectioned with an ultramicrotome, and mounted on the 150-mesh TEM grids. The sections were then stained again with uranyl acetate (25 min) and lead citrate (10 min) for TEM image analysis. The images were acquired with a Philips EM 420 at 80 kV.

### MRI Experiments

200 000 HeLa cells were incubated with nanoparticles and mixed into 2% agarose gel at 40 °C before imaging. Transverse T2-weighted spin-echo images were acquired with a 3-Tesla Siemens Tim Trio MR Scanner. Gel preparations in 2-mL vials were placed in a holder for insertion into the 8-channel volume head resonator. The long axis of the vials was parallel to the static magnetic field, and a transverse tomographic plane orientation was used. A gradient echo acquisition was used with a repetition time of 2000 ms, an echo time of 1.8 ms, a slice thickness of 12 mm, and a flip angle of 20°. In-plane resolution was 0.88 mm. The normal first-order shim process was applied, and the phantoms were imaged at room temperature (20 °C).

### Acknowledgements


The work was supported by the NIH (1R21A12859-01), the Ittleson Foundation, the Dr. Ralph and Marian Falk Medical Research Trust, the Salomon Award from Brown University, the Frontier Research Award from the Department of Chemistry, Brown University, and in part by DARPA/ONR (No. N00014-01-1-0885) and the New England Regional Center of Excellence. We thank Professor Jianghong Rao and Yan Zhang at Stanford University for providing us with NLS peptide, and Professor Minsoo Kim at Brown University for help with fluorescence microscopy.

### References


- [1]. Ferrari M. Nat. Rev. Cancer 2005;5:161–171. [PubMed: 15738981]
- [2]. Pankhurst QA, Connolly J, Jones SK, Dobson J. J. Phys. D: Appl. Phys 2003;36:R167–R181.
- [3]. Mornet S, Vasseur S, Grasset F, Duguet E. J. Mater. Chem 2004;14:2161–2175.
- [4]. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Drug Dev. Res 2006;67:70–93.
- [5]. Bulte JWM, Kraitchman DJ. NMR Biomed 2004;17:484–499. [PubMed: 15526347]
- [6]. Huh YM, Jun YW, Song HT, Kim S, Lee JH, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J. J. Am. Chem. Soc 2005;127:12387–12391. [PubMed: 16131220]
- [7]. Brannon-Peppas L, Blanchette JO. Adv. Drug Delivery Rev 2004;56:1649–1659.

- [8]. Dobson J. *Drug Dev. Res* 2006;67:55–60.
- [9]. Jordan A, Scholz R, Wust P, Föhling H, Felix R. *J. Magn. Magn. Mater* 1999;201:413–419.
- [10]. Ivkov R, DeNardo SJ, Daum W, Foreman AR, Goldstein RC, Nemkov VS, De Nardo GL. *Clin. Cancer Res* 2005;11:7093s–7103s. [PubMed: 16203808]
- [11]. Hilger I, Hergt R, Kaiser WA. *J. Magn. Magn. Mater* 2005;293:314–319.
- [12]. Rockenberger J, Scher EC, Alivisatos AP. *J. Am. Chem. Soc* 1999;121:11595–11596.
- [13]. Hyeon T, Lee SS, Park J, Chung Y, Na HB. *J. Am. Chem. Soc* 2001;123:12798–12801. [PubMed: 11749537]
- [14]. Sun SH, Zeng H. *J. Am. Chem. Soc* 2002;124:8204–8205. [PubMed: 12105897]
- [15]. Sun SH, Zeng H, Robinson DB, Raoux S, Rice PM, Wang SX, Li GX. *J. Am. Chem. Soc* 2004;126:273–279. [PubMed: 14709092]
- [16]. Xie J, Xu CJ, Xu ZC, Hou YL, Young KL, Wang SX, Pourmond N, Sun SH. *Chem. Mater* 2006;18:5401–5403. [PubMed: 18176627]
- [17]. Frankel AD, Pabo CO. *Cell* 1988;55:1189–1193. [PubMed: 2849510]
- [18]. Vives E, Brodin P, Lebleu B. *J. Biol. Chem* 1997;272:16010–16017. [PubMed: 9188504]
- [19]. Josephson L, Tung CH, Moore A, Weissleder R. *Bioconjugate Chem* 1999;10:186–191.
- [20]. Lewin M, Carlesson N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder D. *Nat. Biotechnol* 2000;18:410–414. [PubMed: 10748521]
- [21]. Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, Franzen S, Feldheim DL. *J. Am. Chem. Soc* 2003;125:4700–4701. [PubMed: 12696875]
- [22]. de La Fuente JM, Berry CC. *Bioconjugate Chem* 2005;16:1176–1180.
- [23]. Rajh T, Chen LX, Lukas K, Liu T, Thurnauer MC, Tiede DM. *J. Phys. Chem. B* 2002;106:10543–10552.
- [24]. Xu CJ, Xu KM, Gu HW, Zheng RK, Liu H, Zhang XX, Guo ZH, Xu B. *J. Am. Chem. Soc* 2004;126:9938–9939. [PubMed: 15303865]
- [25]. Storm G, Belliot SO, Daemen T, Lasic DD. *Adv. Drug Delivery Rev* 1995;17:31–48.
- [26]. Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. *Adv. Drug Delivery Rev* 1995;16:215–233.
- [27]. Kapuscinski J. *Biotech. Histochem* 1995;70:220–233. [PubMed: 8580206]
- [28]. Gao H, Shi W, Freund LB. *Proc. Natl. Acad. Sci. USA* 2005;102:9469–9474. [PubMed: 15972807]
- [29]. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. *Proc. Natl. Acad. Sci. USA* 2001;98:8786–8791. [PubMed: 11438707]






**Figure 1.**  $\text{Fe}_3\text{O}_4$  nanoparticles used in the study: a) Schematic illustration (not to scale) of the functionalized nanoparticles of NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$ . b) TEM image of the 9-nm  $\text{Fe}_3\text{O}_4$  nanoparticles coated with oleate/oleylamine. c) TEM image of the 9-nm  $\text{Fe}_3\text{O}_4$  nanoparticles coated with the surfactant shown in a).




**Figure 2.** Hydrodynamic diameters of a) the synthesized  $\text{Fe}_3\text{O}_4$  nanoparticles in hexane, b) PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in water, c) NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS and d) NLS-biotin-NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS. The diameters were measured by DLS. The following parameters were used for size estimation: refractive index 2.420 ( $\text{Fe}_3\text{O}_4$ ), 1.373 (hexane), 1.33 (water); viscosity 0.3000 (hexane), 0.8872 (water); absorption 0.010 ( $\text{Fe}_3\text{O}_4$ ).






**Figure 3.** Gel electrophoresis of a) NaOOC-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> and b) NAv-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles. Both particle dispersions were run on agarose gel (0.5% w/v, 120 min, 100 V) in TAE buffer (40 mM Tris-acetate and 1 mM EDTA, pH 8.3).




**Figure 4.** Average hydrodynamic diameters of the  $\text{Fe}_3\text{O}_4$  nanoparticles in buffers: a) NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS (pH 7.4), b) NLS-NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS, c) NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS+10% FBS, d) NLS-NAV-PEG-DPA- $\text{Fe}_3\text{O}_4$  nanoparticles in PBS + 10% FBS.



**Figure 5.**

Characterization of the nanoparticles in HeLa cells: a) Fluorescent microscopic images of the HeLa cells incubated with RA-labeled VKRKKK-biotin-NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles (0.01 mg Fe mL<sup>-1</sup>) and b) the cells counterstained with DAPI; c) overlap image of a) and b); d) fluorescence microscope images of the HeLa cells incubated with RA-labeled NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles (0.01 mg Fe mL<sup>-1</sup>) and e) the cells counterstained with DAPI; f) overlap image of d) and e); g) plot of the iron concentration within each HeLa cell that was incubated with VKRKKK-biotin-NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> (black column) and NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> (white column) nanoparticles with different concentrations of iron; h) MRI of the HeLa cells containing VKRKKK-biotin-NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles (the first row),

NAV-PEG-DPA-Fe<sub>3</sub>O<sub>4</sub> nanoparticles (the second row); and no nanoparticles (control, the third row).



**Figure 6.** TEM images of the nanoparticles in one HeLa cell: a) The NLS nanoparticles around cell membrane and cytoplasm area; b) the NLS nanoparticles in the cell nucleus; c) a close-up view of the white box area in b); d) the NAV nanoparticles enriched outside the nuclear membrane area.